Clinical trial

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Active, not recruiting · Phase 2 · 1 countries · Registry ID NCT07505303

Active, not recruitingPhase 2Interventional

What this study is about

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 75 Years
SexAll
Healthy volunteersAccepted
ConditionAdult Obesity, Weight Management

Full registry criteria

Inclusion Criteria: 1. Capable of providing written informed consent and complying with all trial procedures. 2. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential). 3. Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening. 4. HbA1c ≤6.5%. 5. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula). 6. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF \>8% at baseline (Week 9). Exclusion Criteria: 1. History or current diagnosis of type 1 or type 2 diabetes mellitus. 2. Weight change \>5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication. 3. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome. 4. Use of GLP-1 agonist treatment within the last 6 months prior to screening. 5. History or current evidence of a pituitary disorder. 6. Have current treatment with or history (within 3 months prior to screening) of treatment with medications that may cause significant weight gain. 7. ALT or AST \>1.5×ULN, or ALP \>1.5×ULN at screening. 8. Documented evidence or clinical signs/symptoms of advanced liver disease including liver cirrhosis, portal hypertension, or hepatic decompensation. 9. History of significant alcohol consumption for \>3 consecutive months within a year prior to screening. 10. Current or past therapy with THR-β agonists (eg, resmetirom). 11. Active untreated hyperthyroidism or hyperthyroidism currently treated with antithyroid medications including methimazole or propylthiouracil. 12. Clinically significant thyroid dysfunction including uncontrolled hypothyroidism or hyperthyroidism. 13. History of bariatric surgery, fitting of a weight loss device, or intestinal bypass surgery within 5 years prior to screening. 14. History of major surgery within 8 weeks prior to screening. 15. Clinically relevant acute or chronic medical condition or unstable disease of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic system.

Treatments and study arms

ECC4703

Drug

orally QD

Placebo

Drug

orally QD

Semaglutide

Drug

SC once weekly

Primary outcomes

Percentage Change in Body Weight from Baseline (Week 9) to Week 20Baseline (Week 9) to Week 20
Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20Baseline (Week 9) to Week 20
Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisBaseline (Week 9) to Week 20
Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisBaseline (Week 9) to Week 20
Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFFBaseline (Week 9) to Week 20

Study locations

15 locations were listed when this page was built. The first 40 are shown.

Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS🇺🇸 Anaheim, California, United States
Atlanta Center for Medical Research - CenExel ACMR - PPDS🇺🇸 Atlanta, Georgia, United States
Central Research Associates - Flourish - PPDS🇺🇸 Birmingham, Alabama, United States
Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS🇺🇸 Cincinnati, Ohio, United States
Velocity Clinical Research - Dallas - PPDS🇺🇸 Dallas, Texas, United States
iResearch Atlanta - CenExel - PPDS🇺🇸 Decatur, Georgia, United States
Velocity Clinical Research - Durham - PPDS🇺🇸 Durham, North Carolina, United States
Velocity Clinical Research - Providence - PPDS🇺🇸 East Greenwich, Rhode Island, United States
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS🇺🇸 Los Alamitos, California, United States
AES - DRS - Optimal Research Florida - Melbourne🇺🇸 Melbourne, Florida, United States
Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS🇺🇸 Omaha, Nebraska, United States
AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis🇺🇸 Richfield, Minnesota, United States
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio🇺🇸 San Antonio, Texas, United States
Flourish Research - San Antonio - PPDS🇺🇸 San Antonio, Texas, United States
ForCare Clinical Research - CenExel FCR - PPDS🇺🇸 Tampa, Florida, United States